Hexosaminidase as a new potential marker for middle ear cholesteatoma

Olszewska, Ewa; Borzym‐Κluczyk, Małgorzata; Olszewski, Sławomir; Rogowski, Marek; Zwierz, Krzysztof

doi:10.1016/j.clinbiochem.2006.08.012

Cited by 8 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, higher levels of N-acetyl-β-hexosaminidase (HEX) were found in cholesteatoma tissues compared to retroauricular skin of the same patients. These results attracted the attention towards the role of HEX in the destructive behavior of cholesteatoma [76,77]. Furthermore, Olszewska et al [78] found higher serum concentration of HEX, β-glucuronidase, and β-galactosidase with resultant increase in glycoconjugate catabolism in the serum of cholesteatoma patients in comparison to healthy subjects.…”

Section: Mechanisms Of Bone Resorption In Cholesteatomamentioning

confidence: 99%

Pathogenesis and Bone Resorption in Acquired Cholesteatoma: Current Knowledge and Future Prospectives

Hamed

Nakata

Sayed

et al. 2016

Clin Exp Otorhinolaryngol

View full text Add to dashboard Cite

Cholesteatoma is a cystic non tumorous lesion of the temporal bone that has the ability to destroy nearby structures by its power to cause bone resorption and as a result, fatal complications prevail. We aimed to conduct a comprehensive review for pathogenesis of acquired cholesteatoma, bone resorption mechanisms, and offer a future vision of this serious disease. We have reviewed different theories for pathogenesis of acquired cholesteatoma including the most relevant and updated ones with special emphasis on the mechanisms of bone resorption through Medline/PubMed research using the keywords ‘aetiopathogenesis, bone resorption, acquired cholesteatoma, temporal bone, and cytokines.’ In order to strengthen our study, we searched the reference lists of identified reviews. Cholesteatoma is a subject of debate among otolaryngologists since it was prescribed firstly. Over many decades, several theories were postulated for aetiopathogenesis of cholesteatoma with a tendency to follow more than one theory to explain the proper nature of that disease. Until now, the mechanism of bone resorption has yet to be more clarified. In the last century, a leap has occurred in the field of biomolecular cholesteatoma research which improved our knowledge about its pathophysiology and bone destructive mechanism. However, surgery is still the only available treatment. We conclude that discovery of new therapeutic choices for cholesteatoma other than surgery by the use of anti-growth, anti-proliferative, apoptotic agents as well as medications that antagonize osteoclastogenesis should be the main concern in the future clinical and experimental research work. Also, searching for predictors of the aggressiveness of cholesteatoma can affect the timing of intervention and prevent occurrence of complications.

show abstract

Section: Mechanisms Of Bone Resorption In Cholesteatomamentioning

confidence: 99%

Pathogenesis and Bone Resorption in Acquired Cholesteatoma: Current Knowledge and Future Prospectives

Hamed

Nakata

Sayed

et al. 2016

Clin Exp Otorhinolaryngol

View full text Add to dashboard Cite

show abstract

“…The most important for their osteolytic activity are cathepsins D and K, metalloproteinase 9, reduced nicotinamide adenine dinucleotide phosphate oxidase, and lysosomal exoglycosidases. 27,28…”

Section: Discussionmentioning

confidence: 99%

Catabolism of Glycoconjugates in Chronic Otitis Media with Cholesteatoma

Olszewska

Borzym‐Κluczyk

Olszewski

et al. 2007

Journal of Investigative Medicine

Self Cite

View full text Add to dashboard Cite

Chronic ear disease with cholesteatoma is characterized by an intrusion of keratinizing stratified squamous epithelium into the middle ear manifesting bone resorption at the interface of the perimatrix. The aim of our study was to investigate the markers of a catabolic process associated with several chronic inflammatory states. We assessed the level of catabolism of glycoconjugates in assays of cholesteatoma extracts, quantifying two lysosomal exoglycosidases: alpha-mannosidase (alpha-MAN) and beta-galactosidase (beta-GAL). Cholesteatomas (n = 15) and normal adult postauricular skin served as controls (n = 15) were collected from the patients during surgery owing to chronic otitis media. To assess exoglycosidase activity, release of p-nitrophenol from p-nitrophenol derivatives of alpha-mannose and beta-galactose was used. In 13 of 15 specimens, we observed significantly higher activity of investigated enzymes in cholesteatoma tissue compared with control tissue (postauricular skin). The mean activity of alpha-MAN from the cholesteatoma cells was 1.76 +/- 1.10 nkat/g wet tissue and 0.61 +/- 0.21 nkat/g wet tissue in the control probes. The mean activity of beta-GAL from the cholesteatoma cells was 1.77 +/- 1.07 nkat/g wet tissue and 0.87 +/- 0.20 nkat/g wet tissue in the control probes. Catabolic reactions involving glycoproteins, glycolipids, and proteoglycans may play a role in cholesteatoma-related bone resorption. The present data indicating that the lysosomal exoglycosidases alpha-MAN and beta-GAL are significantly and consistently elevated suggest the need to further correlations assessment between levels of alpha-MAN and beta-GAL and cholesteatoma behavior. Further research should also evaluate the relative importance of these particular exoglycosidases in manifesting bone resorption in considering the spectrum of identified inflammatory mediators.

show abstract

“…An example is HEX, a novel potential marker of cholesteatoma [8]. The mean activity of HEX in cholesteatoma (68.55 ± 30.77 nkat/g of wet tissue) was significantly higher than in skin (31.79 ± 10.02 nkat/g of wet tissue).…”

Section: Tissue Exoglycosidase Activity As a Marker Of Many Diseasesmentioning

confidence: 98%

Exoglycosidase markers of diseases

Chojnowska

Kępka

Szajda

et al. 2011

Biochemical Society Transactions

Self Cite

View full text Add to dashboard Cite

Exoglycosidases are hydrolases involved in lysosomal degradation of oligosaccharide chains of glycoconjugates (glycoproteins, glycolipids and proteoglycans). In tissues and body fluids, a higher exoglycosidase specific activity is found in N-acetyl-β-hexosaminidase, than β-glucuronidase, α-L-fucosidase, β-galactosidase, α-mannosidase and α-glucosidase. Determination of exoglycosidases (especially N-acetyl-β-hexosaminidase and β-glucuronidase) in body fluids could be an inexpensive, easy to perform and sensitive test for pathological evaluation, as well as in screening and monitoring many diseases, including alcohol abuse, risk of arteriosclerosis, bacterial infections (e.g. Lyme borreliosis), chronic inflammatory processes, such as rheumatoid arthritis and juvenile idiopathic arthritis, asthma, autoimmune hepatitis and primary biliary cirrhosis, as well as cancers.

show abstract

Hexosaminidase as a new potential marker for middle ear cholesteatoma

Cited by 8 publications

References 9 publications

Pathogenesis and Bone Resorption in Acquired Cholesteatoma: Current Knowledge and Future Prospectives

Pathogenesis and Bone Resorption in Acquired Cholesteatoma: Current Knowledge and Future Prospectives

Catabolism of Glycoconjugates in Chronic Otitis Media with Cholesteatoma

Exoglycosidase markers of diseases

Contact Info

Product

Resources

About